Alvotech Strikes $45m Deal With Yas
Biosimilars Deal Includes 2.5% Stake And MENA Rights
Alvotech has struck an investment deal worth $45m with Yas Holding that will give Yas a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.
You may also be interested in...
Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.